Aryl hydrocarbon receptor market seen reaching $7.12 billion by 2030

By AI, Created 9:53 AM UTC, May 20, 2026, /AGP/ – The global aryl hydrocarbon receptor market is projected to grow from $5.34 billion in 2026 to $7.12 billion by 2030, driven by autoimmune disease prevalence, immunotherapy research and rising biotech investment. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The aryl hydrocarbon receptor market is tied to treatments for autoimmune and inflammatory diseases, making its growth relevant to drug development and immune-focused research. - Rising disease prevalence and expanding clinical activity are increasing demand for AHR-targeted therapies and related research tools.

What happened: - The Business Research Company released its Aryl Hydrocarbon Receptor Global Market Report 2026, covering market size, trends and forecasts through 2035. - The market grew from $4.97 billion in 2025 to $5.34 billion in 2026. - The report projects the market will reach $7.12 billion by 2030. - The report places the market in London, Greater London, United Kingdom, and was dated May 8, 2026. - A free sample of the report is available. - The full market report is also available online.

The details: - The market posted a 7.5% compound annual growth rate in the prior period and is forecast to keep growing at 7.5% through 2030. - Growth drivers include breakthroughs in molecular biology, higher autoimmune disease prevalence, stronger academic research, more biotechnology funding and better receptor-targeting methods. - Future growth is expected to come from novel immunotherapies, precision medicine, more investment in inflammation research, more clinical trials and new biotech startups. - Key trends include selective AHR modulators, accelerated immune-modulation research, greater focus on autoimmune and inflammatory diseases, more preclinical and early-stage trials, and deeper pharma-biotech collaborations. - The aryl hydrocarbon receptor interacts with environmental toxins such as dioxins and helps regulate gene expression involved in immune and inflammatory responses. - Researchers are targeting the receptor selectively to activate or inhibit its function in diseases such as psoriasis. - AHR agonists have therapeutic potential because they can regulate immune responses, including T-cell differentiation and immune cell function. - The report says North America held the largest market share in 2025. - The report expects Asia-Pacific to be the fastest-growing region in the coming years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market thesis is being shaped less by consumer demand and more by pipeline-building in autoimmune and inflammatory medicine. - The combination of rising diagnosis rates, research funding and trial activity suggests the market is moving from basic science toward commercial drug development. - The regional split points to established research strength in North America and faster capacity buildout in Asia-Pacific. - A May 2023 University of Oxford study found autoimmune disorders affect roughly one in 10 people, including 13% of women and 7% of men across 19 studied diseases.

What’s next: - The Business Research Company expects the market to keep expanding as immunotherapy programs and precision medicine platforms advance. - More preclinical work and early-stage trials are likely to shape the competitive landscape through 2030. - Pharma and biotech partnerships are expected to remain a key part of market development.

The bottom line: - Aryl hydrocarbon receptor research is moving into a broader commercial phase, supported by autoimmune disease burden, drug-development activity and steady global market growth.